FDA declines to grant EUA for Humanigen’s Covid-19 antibody lenzilumab
FDA was unable to conclude the benefit-risk profile of lenzilumab as Covid-19 treatment and sought...
News
Sanofi agrees to acquire biopharma company Kadmon for $1.9bn
Sanofi’s acquisition of Kadmon will help in advancing the growth of its General Medicines core...
Exscientia signs deal to develop anti-viral treatments for various viruses
The Gates Foundation will make a $35m equity investment in Exscientia to develop various therapies.
AIM seeks FDA approval to study Ampligen for Covid-19
The two-arm, randomised trial will enrol 80 subjects with PCCD to evaluate Ampligen’s efficacy and...
Adaptimmune and Genentech partner for allogeneic cell therapies development
Adaptimmune will receive an upfront payment of $150m from Genentech and further payments of $150m...
Takeda to deliver Novavax’s Covid-19 vaccine doses to Japan
Takeda plans to supply the vaccine doses earlier next year on obtaining approval from the country’s MHLW.
EnGeneIC initiates Phase I trial of nanocellular anti-Covid-19 vaccine
Stored at room temperature, the vaccine has a shelf life of more than three years, facilitating easy transportation.
NeuExcell and Spark partner to develop gene therapy for Huntington’s
Under the agreement, Spark will access the neuro-regenerative gene therapy platform of NeuExcell to develop the new treatment.
EMA begins analysis of Pfizer-BioNTech’s Covid-19 booster shot data
The variation submitted by the companies includes Phase III trial data from 306 subjects who received the third vaccine dose.
Concern over COVID-19 rises in August for second straight month: Poll
The health concern over COVID-19 increased in August for the second consecutive month, shows the COVID-19 concern index, which is measured by responses to an ongoing poll Verdict launched in March 2020. The poll has...
Hetero obtains DCGI approval to produce Roche’s Covid-19 drug in India
The company plans to make tocilizumab available under the brand name Tocira in India by this month end.
